Search
Close this search box.

New Oncolines publication in Cancers

IL4I1 in ascites as a marker in high-grade serous ovarian cancer

The emergence of immunotherapy has revolutionized cancer treatment for various malignancies. However, immunotherapies have demonstrated only limited efficacy in ovarian cancer, which may be explained by the highly immunosuppressive nature of the ovarian tumor microenvironment. Enzymes that catabolize amino acids critical for adequate T cell responses, such as tryptophan, or produce metabolites that inhibit immune cell function may contribute to this immunosuppressive environment.

In a recent paper published in Cancers,1 Yvonne Grobben from Oncolines investigated the role of various immunosuppressive amino acid-metabolizing enzymes in high-grade serous ovarian cancer. Through targeted liquid chromatographytandem mass spectrometry (LC-MS/MS)-based metabolomics, the activity of well-known immunotherapeutic drug targets, such as indoleamine 2,3-dioxygenase (IDO1) and arginase 1 (ARG1), was measured in plasma and ascites samples collected from patients with advanced stages of the disease. Ascites is the abnormal buildup of fluid frequently found in the abdomen of women with ovarian cancer. The levels of metabolites produced by the l-amino acid oxidase ‘interleukin 4 induced 1’ (IL4I1) were also measured. IL4I1 was recently proposed to play a role in resistance to IDO1 inhibitor therapy.2

By comparing amino acid and metabolite levels in plasma and ascites, Grobben showed that ascites is a valuable source of biomarkers related to amino acid-derived metabolites. High levels of IL4I1-associated metabolites were found in this fluid and correlated significantly with the concentration of secreted IL4I1. Moreover, levels of these metabolites were elevated in patients with stage IV compared to stage III disease, suggesting an involvement of IL4I1 in disease progression. Analysis of pleural effusions from non-small cell lung cancer patients additionally indicated that enhanced activity of IL4I1 is not limited to ovarian cancer, suggesting a potential role for this enzyme across cancer types. The studies provide support for IL4I1 as a potential novel small molecule drug target for cancer immunotherapy. Moreover, the described LC-MS/MS methods can be used for evaluation of biomarkers for patient stratification and measurement of target engagement of IL4I1 inhibitors, which are currently in development.3

The study was performed in collaboration with Utrecht University and Radboud University Medical Center (Radboudumc, Nijmegen) in the Netherlands, and Pangaea Oncology, S.A. in Barcelona (Spain). Samples from ovarian cancer patients were collected by researchers from Radboudumc in a project supported by Foundation Ruby and Rose. Lung cancer pleural effusions were provided by Pangaea Oncology, with whom Oncolines collaborates in a Eurostars-funded project.

Oncolines B.V. is a precision medicine services company in oncology and cancer immunotherapy. Oncolines is part of the Symeres group of companies, a group of high-quality CROs and CDMOs based in Europe and the United States.

References

  1. Grobben Y, den Ouden JE, Aguado C, van Altena AM, Kraneveld AD, Zaman GJR (2023) Amino Acid-Metabolizing Enzymes in Advanced High-Grade Serous Ovarian Cancer Patients: Value of Ascites as Biomarker Source and Role for IL4I1 and IDO1. Cancers. 15(3):893.
  2. Sadik et al. (2020) IL4I1 Is a Metabolic Immune Checkpoint That Activates the AHR and Promotes Tumor Progression. 182(5):1252–1270.
  3. MacKinnon et al. (2020) Anti-tumor activity of CB-668, a potent, selective and orally bioavailable small-molecule inhibitor of the immuno-suppressive enzyme Interleukin 4 (IL-4)-Induced Gene 1 (IL4I1). J Immunother Cancer. 8(Suppl 3):A747.

Are you ready to make your mark and improve global health together as an innovator or as a service provider in the park? Join our community

Pivot Park Captains' Dinner

10 years ago, Pivot Park opened its doors to the world. Thanks to your commitment, support and confidence, we have been able to grow it into the successful and innovative biopharmaceutical campus it is today.

Now it’s time to celebrate!

We are therefore delighted to invite you – along with all your fellow CEOs at Pivot Park – to a special night out featuring inspiring art, a wonderful dinner and lots of opportunities to network and exchange ideas.

Erwin Wurm | Am I a House?

For the first time, the artist shows a cross-section of his work, from Narrow Furniture to One Minute Sculptures, within the walls of a historic building. Villa Constance, a former home that today houses Museum Jan Cunen, is not only a location but also part of the conversation. Because what exactly is a house?

#100YEARSPHARMAFUTURE

The development of medicines in Oss began one hundred years ago. It was then that the foundations were laid for what would become a flourishing pharmaceutical sector in the Netherlands, leading to groundbreaking discoveries such as insulin and the anti-conception pill.

Today, the entire chain is still represented in Oss, from early-stage research to the commercial scale production of medicines. Working in Oss, we focus on the health of people all over the world. Employees at dozens of companies large and small put their heart and soul into new medicines, products and services that will improve lives worldwide. Together, our strength lies in our combination of broad knowledge about the development of medicines and a thorough understanding of the requirements of high-quality production.

This shared past and common values stimulate strong bonds among everyone who works in pharmaceuticals in Oss. We build on qualities, expertise and networks that go back decades. And with a wide variety of pharmaceutical companies, suppliers and scientific institutions all located nearby, we offer an attractive business climate and an excellent basis for international collaboration.

We are proud to work together to create a better and healthier future for all, a collaboration that in turn fuels growing employment: today, most pharmaceutical jobs in the Netherlands are in Oss. Here we connect talent and companies and stimulate entrepreneurship, while our expert employees are our most important asset. Their drive ensures that Oss has an influence on health all over the world.

Pharma in Oss offers endless opportunities to startups and talent in a city and region that is a joy to live and work in. We are committed to collaboration and sustainable and successful entrepreneurship. Oss’s pharmaceutical companies are intrinsically competitive while also being committed to quality and safety. This, plus their focus on new health solutions and contemporary technology, makes us a leader in our pursuit of a better life for people worldwide.